- Home
- EWCZ vs PRQR Comparison
EWCZ vs PRQR Comparison
Compare EWCZ & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWCZ | PRQR |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 250.7M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EWCZ | PRQR |
|---|---|---|
| Price | $3.83 | $2.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $5.50 | ★ $8.14 |
| AVG Volume (30 Days) | 348.3K | ★ 558.5K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.45 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $211,264,000.00 | $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $15.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $1.07 |
| 52 Week High | $7.60 | $3.46 |
Technical Indicators
Market Signals| Indicator | EWCZ | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 58.54 |
| Support Level | $3.87 | $2.15 |
| Resistance Level | $4.33 | $2.42 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 21.37 | 96.46 |
Price Performance
Historical ComparisonAbout EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.